NDTVCenter·
Jubilant Pharmova Q2 Review: Nirmal Bang Raises Target Price, Bets On H2 Margin Recovery
Nirmal Bang believes the FY28 ramp-up in Line 3, Line 4, and the PET network, together with SPECT normalisation, gives enough visibility for Jubilant Pharmova's stronger earnings.
Read at NDTV →



